Early cost-effectiveness analysis of risk-based selection strategies for adjuvant treatment in stage II colon cancer: the potential value of prognostic molecular markers

BACKGROUND: To explore the potential value of Consensus Molecular Subtypes (CMS) in stage II colon cancer (CC) treatment selection, we carried out an early cost-effectiveness assessment of a CMS-based strategy for adjuvant chemotherapy. METHODS: We used a Markov cohort model to evaluate three select...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Epidemiol Biomarkers Prev
Autori principali: Jongeneel, Gabrielle, Greuter, Marjolein J.E., Kunst, Natalia, van Erning, Felice N., Koopman, Miriam, Medema, Jan P., Vermeulen, Louis, Ijzermans, Jan N.M., Vink, Geraldine R., Punt, Cornelis J.A., Coupé, Veerle M.H.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7611620/
https://ncbi.nlm.nih.gov/pubmed/34162659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-21-0078
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi